Skip to main navigation Skip to search Skip to main content

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

  • L H Sehn
  • , N Chua
  • , J Mayer
  • , G Dueck
  • , M Trneny
  • , K Bouabdallah
  • , N Fowler
  • , V Delwail
  • , O Press
  • , G Salles
  • , J Gribben
  • , A Lennard
  • , Elly Lugtenburg
  • , N Dimier
  • , E Wassner-Fritsch
  • , G Fingerle-Rowson
  • , BD Cheson

Research output: Contribution to journal › Article › Academic › peer-review

327 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)1081-1093
Number of pages13
JournalLancet Oncology
Volume17
Issue number8
DOIs
Publication statusPublished - 2016

Research programs

  • EMC MM-02-41-03

Cite this